Skip to main content

Drug Interactions between anti-inhibitor coagulant complex and coagulation factor Xa

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

anti-inhibitor coagulant complex coagulation factor Xa

Applies to: anti-inhibitor coagulant complex and coagulation factor Xa

Consumer information for this interaction is not currently available.

GENERALLY AVOID: The safety of andexanet alfa (recombinant coagulation factor Xa) has not been evaluated in patients who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood within seven days prior to the bleeding event, as they were excluded from clinical trials.

MANAGEMENT: Pro-coagulant factor treatments (e.g., 3- or 4-factor prothrombin complex concentrates (PCCs), activated PCC, recombinant factor VIIa, fresh frozen plasma) and whole blood should be avoided during treatment with andexanet alfa unless absolutely required.

References

  1. "Product Information. Andexxa (coagulation factor Xa)." Portola Pharmaceuticals (2022):
  2. "Product Information. Ondexxya (coagulation factor Xa)." AstraZeneca UK Ltd (2022):
  3. "Product Information. Andexxa (coagulation factor Xa)." AstraZeneca Pty Ltd (2023):

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer